Skip to content

FDA advisory panel says yes to tipranavir

Human growth hormone reverses HIV-associated wasting and improves exercise performance

Interleukin-2 causes bigger CD4 responses with more treatment cycles and undetectable viral load

BHIVA issues draft 2005 treatment guidelines, calls for comments by May 3rd

Tarnished hydroxyurea less toxic, more potent at lower doses, according to RIGHT study

European activists claim Pfizer's CCR5 antagonist trial unnecessarily putting most vulnerable at risk; US activists disagree

Test tube study shows how resting CD4 T-cells avoid infection with HIV

Gilead acquires HIV integrase inhibitor from Japan Tobacco

CCR5 antagonists unlikely to aggravate hepatitis C infection, French study reports